Ligand Pharmaceuticals Inc. (Nasdaq: LGND) announced it has acquired an ascending tiered royalty interest in Santen Pharmaceutical Co., Ltd.'s Ryjunea from Sydnexis, Inc. for a $23 million upfront ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results